Only 40.6% of patients on mitapivat in the RISE UP Phase 3 trial achieved the primary hemoglobin response endpoint, yet that subgroup is now driving the entire clinical narrative around Agios’s sickle cell program. That asymmetry matters enormously for what comes next. The full 52-week data, presented at the EHA 2026 Plenary Session in Stockholm, confirmed statistically significant hemoglobin improvement versus placebo, but the headline pain crisis endpoint did not reach significance in the overall population. What Agios brought to EHA are new analyses showing that among responders, the anti-hemolytic signal translates into something operationally tangible: a 41.1% relative reduction in the proportion of patients requiring blood transfusions and a 55.9% relative reduction in average red blood cell units transfused per patient compared with placebo.
The responder post-hoc data are genuinely granular. Patients who achieved hemoglobin response (defined as at least a 1.0 g/dL increase from baseline sustained from Week 24 through Week 52, with a mean increase of 1.6 g/dL in that group) showed a 26% reduction in annualized sickle cell pain crisis rate compared with non-responders, 34% fewer related hospitalizations, and a 53% drop in emergency room visits for pain crises. PROMIS Fatigue scores improved by 5.19 points in responders versus 2.55 in non-responders, crossing the predefined 4.1-point threshold for clinical meaningfulness. Improvements in pain intensity, sleep, and physical function also favored responders. These are not trivial effect sizes, and the transfusion burden reduction held regardless of whether patients were also on hydroxyurea, which broadens the potential eligible population considerably.
The strategic complication is real and worth naming plainly. Mitapivat’s mechanism as an oral pyruvate kinase activator has already demonstrated efficacy in pyruvate kinase deficiency, where the DRIVE PK Phase 2 study showed 50% of patients achieving a hemoglobin increase exceeding 1.0 g/dL. In sickle cell disease, the responder rate is lower and the responders are not identifiable prospectively. That creates a genuine regulatory and commercial puzzle: how does a label capture a benefit that is only fully visible post-response? The sickle cell treatment landscape already includes approved agents targeting different mechanisms, and Agios must demonstrate that mitapivat’s anti-hemolytic profile offers additive or differentiated value in a real-world prescribing context.
The single marker worth tracking now is how Agios frames the hemoglobin responder definition in its regulatory submissions. If the FDA accepts a responder-enriched label or a response-based treatment continuation criterion, the commercial and reimbursement logic becomes coherent. If not, the gap between the overall trial population results and the subgroup benefit remains the central vulnerability in the program’s path to broad adoption.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
